LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! Today on our Sunday menu, we have six clinical updates and one preclinical dessert. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• Phase 1 Trial: GTB-5550 Immunotherapy Targeting B7-H3
  The GTB-5550 immunotherapy, a TriKE molecule, has received FDA clearance for its first human trial, focusing on advanced prostate cancer patients. This molecule acts as a molecular GPS by binding natural killer (NK) cells via their CD16 receptor and guiding them to attack tumors that overexpress B7-H3, a protein found on nearly all prostate tumors. Beyond just targeting, it incorporates IL-15 to help these immune cells multiply and persist, maintaining their killing effectiveness even in the harsh, low-oxygen environments typically found in prostate tumor cores. Preclinical models demonstrated that GTB-5550 can increase NK cell activity by 3 to 5 times compared to controls, successfully inducing tumor regression in xenograft models.
• Phase 1 Trial: OP-3136 KAT6A/B Inhibitor for mCRPC
  A first-in-human clinical trial has begun recruiting patients with metastatic castration-resistant prostate cancer (mCRPC) to evaluate OP-3136, an orally bioavailable inhibitor of the KAT6A and KAT6B epigenetic regulators. These regulators are involved in oncogenic transcriptional programs, and their selective inhibition represents a novel approach to treating resistant disease. Preclinical data showed that the drug effectively inhibits tumor growth in prostate xenograft models, particularly when combined with docetaxel, where a synergistic effect was observed.​
  ​
• Phase 1/2 Trial: SPR1020 PARP1-Selective Inhibitor
  The SPR1020 trial is an open-label study testing a highly selective PARP1 inhibitor in patients with advanced solid tumors, including prostate cancer, that possess DNA repair deficiencies. Unlike earlier PARP inhibitors that target both PARP1 and PARP2, SPR1020 is designed to spare PARP2, which may help avoid the severe blood count crashes often seen with broader therapies. Furthermore, the drug is designed for brain penetration, offering potential efficacy for patients whose metastatic disease has spread to the central nervous system.​
  ​
• Phase 1/2 Trial: JASPER Study of Ruxolitinib and Enzalutamide
  The JASPER trial explores a new strategy for mCRPC by targeting the JAK/STAT inflammatory signaling axis to prevent cancer cells from becoming “plastic” and resistant to treatment. By combining the JAK1/2 inhibitor ruxolitinib with the standard drug enzalutamide, researchers aim to block the molecular machinery that allows prostate cancer cells to transition into stem-like, hormone-insensitive states. Preclinical research indicates that this combination is selectively synergistic in AR-negative cells, which are often the most difficult to treat because they no longer rely on the androgen receptor for survival.​
  ​
• Phase 2 Trial: Alliance A222001 Study of Oxybutynin for Hot Flashes
  This clinical trial found that oxybutynin, a medication typically used for overactive bladder, is highly effective at reducing hot flashes in men receiving androgen-deprivation therapy. The study revealed that a 5 mg twice-daily dose resulted in a 68 percent reduction in daily hot flashes compared to only 21 percent for a placebo. These improvements occurred rapidly, often within the first week of treatment, and led to significant gains in patient quality of life, including better sleep and overall well-being, with only mild side effects like dry mouth.​
  ​
• WOLVERINE Meta-Analysis of Metastasis-Directed Therapy
  The WOLVERINE study provides high-reliability evidence from an analysis of seven phase 2 trials, showing that metastasis-directed therapy (MDT),such as targeted radiation or surgery, significantly improves outcomes for men with oligometastatic prostate cancer. Adding MDT to standard care resulted in a 14-month gain in median progression-free survival (from 21 to 35 months), extended overall survival and delayed the time until the cancer became resistant to hormone therapy. These benefits were consistent across various patient groups, including those with hormone-sensitive or resistant cancer.​
  ​

Preclinical Research & Reviews

• Dual-Action Nanomaterial for Targeted Cancer Eradication Researchers have developed a groundbreaking iron-based metal-organic framework (MOF) nanoagent that selectively destroys cancer cells by exploiting their acidic and hydrogen peroxide-rich environment. This “chemodynamic therapy” triggers a dual chemical cascade that produces reactive oxygen species (ROS), which overwhelm and kill cancer cells by damaging their DNA and proteins. In animal models, this treatment achieved complete tumor regression and provided long-term protection against recurrence, all while sparing healthy tissues and showing no detectable systemic toxicity.​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max